Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ambrx Biopharma Inc ADR (NY: AMAM )

10.13 UNCHANGED
Last Price Updated: 7:00 PM EDT, Mar 16, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 10.13
Bid (Size) 10.66 (3)
Ask (Size) 11.24 (1)
Prev. Close 10.13
Today's Range 10.13 - 10.13
52wk Range 0.3800 - 13.07
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Shares of Ambrx Biopharma Soared This Week
A big buy by an asset manager spurred interest in the biotech stock. 
Via The Motley Fool
Around $19M Bet On Westrock Coffee? Check Out These 3 Stocks Insiders Are Buying
Although U.S. stocks closed lower on Tuesday, there were a few notable insider trades. 
Via Benzinga

Performance

YTD
+389.37%
+389.37%
1 Month
N/A
N/A
3 Month
N/A
N/A
6 Month
N/A
N/A
1 Year
+846.73%
+846.73%

More News

Read More
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
PTC Therapeutics, Planet Fitness, Kemper And Other Big Stocks Moving Lower On Friday
Via Benzinga
Topics Stocks
Exposures US Equities
Where Ambrx Biopharma Stands With Analysts
Via Benzinga
Expert Ratings for Ambrx Biopharma
Via Benzinga
What 4 Analyst Ratings Have To Say About Ambrx Biopharma
Via Benzinga
Why Shares of Ambrx Biopharma Jumped This Week
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For September 12, 2023
Via Benzinga
Ambrx Biopharma Has Surged 483% This Year. But It Could Just Be Getting Started.
Via Investor's Business Daily
Unique ADC Constructs Boost Ambrx Biopharma's Profile: Analyst Sees Optimistic Outlook
Via Benzinga
Ambrx Biopharma Highlights Preclinical Data From Studies in Kidney, Prostate Cancer
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 31, 2023
Via Benzinga
Investor Opportunities Ahead of Clinical Updates, Says Analyst Initiating Coverage on Ambrx Biopharma with 'Buy' Rating
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 2, 2023
Via Benzinga
Ambrx Biopharma's Oncology Pipeline Is Underappreciated, Analyst Initiating Coverage Says
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 19, 2023
Via Benzinga
Why Sunrise New Energy Shares Are Trading Higher By 35%; Here Are 20 Stocks Moving Premarket
Via Benzinga
$59M Bet On This Biotechnology Stock? Check Out These 4 Stocks Insiders Are Buying
Via Benzinga
Over $25M Bet On This Biotechnology Stock? Check Out These 3 Stocks Insiders Are Buying
Via Benzinga
7 Cheap Stocks That Are Worth Your Attention
Via InvestorPlace
7 Risky Stocks That Are Worth the Stretch
Via InvestorPlace
5 Short Squeeze Candidates To Watch: Ambrx Biopharma, Kala Pharmaceuticals And This Company That Moved Up 1,403 Positions
Via Benzinga
Why RAPT Therapeutics Shares Are Trading Lower By Over 30%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.